MTOR and gastric adenocarcinoma: For example, mTOR hyperactivation was reported in 60%–80% of all gastric adenocarcinomas (Lang et al., 2007; Feng et al., 2008), and inappropriate Akt and p-Akt expression in more than 74% of GC patients (Nam et al., 2003).